共 50 条
- [1] Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine:: the Jena experience in 79 patientsJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (09) : 516 - 524Kliche, KOKubsch, KRaida, MMasri-Zada, RHöffken, K
- [2] Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxaliplatin, 5-FU and sodium folinate in a pilot investigationINTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2006, 44 (03) : 128 - 134Merkel, UFarker, KWedding, URoskos, MHippius, MHöffken, KHoffmann, A
- [3] Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients:: analysis of non-hematological toxicity and patient characteristics in a pilot investigationINTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2006, 44 (01) : 31 - 37Farker, KMerkel, UWedding, UHippius, MHöffken, KHoffmann, A
- [4] A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapyEUROPEAN JOURNAL OF CANCER, 2021, 154 : 288 - 295Choi, In SilKim, Ki HwanLee, Ju HyunSuh, Koung JinKim, Ji-WonPark, Jin HyunKim, Yu JungKim, Jin-SooKim, Jee HyunKim, Jin Won
- [5] Oxaliplatin/5-FU chemotherapy without leucovorin in metastatic colorectal cancer.JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 302S - 302SShim, BYCho, HJYang, JMKim, HJKim, JKKim, HK
- [6] SAFETY AND ACTIVITY OF AN ALTERNATINIG REGIMEN OF IRINOTECAN/5-FU/LV AND OXALIPLATIN/5-FU/LV (FAFOXIRI) IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC)ANNALS OF ONCOLOGY, 2004, 15 : 62 - 63Amoroso, VitoFerrari, VittorioValcamonico, FrancescaVassalli, LuciaSimoncini, EddaGrisanti, SalvatoreMarpicati, PatriziaRangoni, GiovanniMarini, Giovanni
- [7] A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Kim, Jin WonSuh, Koung JinKim, Ji-WonPark, Jin HyunKim, Ki HwanKim, Yu JungKim, Jin-SooKim, Jee HyunChoi, In Sil
- [8] Second line chemotherapy after first line irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI) in metastatic colorectal cancer (MCRC) patients (pts).JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291SMasi, GAllegrini, GMarcucci, LCupini, SBrunetti, IFontana, ERicci, SCerri, EBarbara, CFalcone, A
- [9] A phase II randomized study of Combined Infusional Leucovorin Sodium and 5-FU versus the Leucovorin Calcium followed by 5-FU both in combination with Irinotecan or Oxaliplatin in patients with metastatic colorectal cancerACTA GASTRO-ENTEROLOGICA BELGICA, 2012, 75 (01): : 14 - 21Bleiberg, H.Vandebroek, A.Deleu, I.Vergauwe, P.Kalantari, H. RezaeiD'Haens, G.Paesmans, M.Peeters, M.Efira, A.Humblet, Y.
- [10] Modified FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for gemcitabine-resistant or -refractory advanced pancreatic cancerEUROPEAN JOURNAL OF CANCER, 2015, 51 : S456 - S456Lee, S. C.Lee, K.Bae, S. B.Kim, Han JoOh, S. Y.Song, S. Y.Hong, D. S.Kim, Hyun JungYoon, J.Lim, D. H.Lee, S. I.Won, J. H.Lee, N.Kim, K.Lee, H. W.Lee, H. R.Nam, E. M.Jang, J. S.Hwang, I. G.Kang, J. H.